Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
26.69
+0.28 (1.06%)
Nov 18, 2026, 4:00 PM EST - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $11.26M in the quarter ending September 30, 2026, with 5.86% growth. This brings the company's total for the last twelve months to $28.21M, down -86.28% year-over-year. In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth. That makes Stoke Therapeutics the 31,793rd largest company in the world by revenue and 4,179th in the United States.
Revenue (ttm)
$28.21M
Revenue Growth
-86.28%
P/S Ratio
62.88
Revenue / Employee
$165,941
Employees
170
Market Cap
1.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.96B |
| Vir Biotechnology | 302.80M |
| Zymeworks | 265.97M |
| Agios Pharmaceuticals | 140.84M |
| Mesoblast | 120.25M |
| Recursion Pharmaceuticals | 68.23M |
| Maze Therapeutics | 20.00M |
| Lycia Therapeutics | 4.44M |
STOK News
- 1 day ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 1 day ago - Stoke Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 8 days ago - Stoke Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 15 days ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in November - Business Wire
- 20 days ago - Stoke Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 20 days ago - Stoke Therapeutics Slides: Q3 2026 - Filings
- 20 days ago - Stoke Therapeutics Earnings release: Q3 2026 - Filings
- 20 days ago - Stoke Therapeutics Quarterly report: Q3 2026 - Filings